Welcome to our dedicated page for Tevogen Bio news (Ticker: TVGN), a resource for investors and traders seeking the latest updates and insights on Tevogen Bio stock.
Tevogen Bio Holdings Inc. (TVGN) is a clinical-stage biotechnology company pioneering precision T cell therapies for infectious diseases, cancers, and neurological disorders. This page provides investors and industry professionals with comprehensive updates on Tevogen's scientific advancements, strategic partnerships, and regulatory milestones.
Access real-time news about clinical trial developments, intellectual property achievements, and collaborations driving Tevogen's AI-enhanced drug discovery platform. Our curated collection includes earnings reports, research breakthroughs, and management insights critical for understanding the company's position in the immunotherapy sector.
Key updates cover Tevogen's ExacTcell platform progress, Tevogen.AI innovations, and partnership expansions with technology leaders. Bookmark this page to stay informed about FDA submissions, trial results, and market-moving announcements from one of biotech's most innovative companies.
Tevogen Bio Holdings (Nasdaq: TVGN) announces CEO Dr. Ryan Saadi's participation in BioNJ's Fifteenth Annual Bio Partnering Conference on May 13, 2025, at The Liberty Science Center in Jersey City. Dr. Saadi will join a panel discussion titled 'Paths to Liquidity: Strategies for Adapting to a Volatile Market,' alongside executives from J.P. Morgan, RSM, and Cantor Fitzgerald.
The conference aims to connect investors, BD professionals, academic collaborators, and biopharmaceutical industry executives to promote strategic partnerships, funding opportunities, and healthcare innovation. The event features 1:1 partnering sessions, company pitch presentations, Industry Connections Desk, exhibits, and networking opportunities.
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has announced the launch of Tevogen Generics, a new initiative aimed at domestic manufacturing of unbranded pharmaceuticals and APIs. This effort aligns with President Trump's recent tariff-related statements and national focus on pharmaceutical affordability.
The company has appointed Sadiq Khan, MBA, the current Chief Commercial Officer, as Interim Head of this new venture. Tevogen Generics becomes the company's third strategic pillar, alongside:
- Tevogen Bio - specialty immunotherapy biotech focusing on off-the-shelf, precision T cell therapies
- Tevogen.AI - utilizing artificial intelligence for drug discovery and healthcare delivery optimization
- Tevogen Generics - focused on making essential medicines accessible
Tevogen Bio Holdings (Nasdaq: TVGN) participated in the AI x Bio Philly event, showcasing the intersection of artificial intelligence and life sciences in Philadelphia. Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, presented alongside leaders from BioCurie, BioPhy AI, and Proscia during the AI Demos and Presentations session.
Mehta's presentation highlighted Tevogen.AI's proprietary AI technology, which aims to accelerate the development of off-the-shelf precision T cell therapies through computational modeling of T cell receptor (TCR) engagement with immunologically active HLA+ peptide complexes. The event was hosted by BioBuzz, BitsInBio, Atria, and Zetta, bringing together innovators, entrepreneurs, and investors in the biotechnology sector.
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has announced that company insiders, including executive officers and board members, currently hold approximately 74% of outstanding shares as of April 7, 2025. This significant insider ownership demonstrates management's confidence in the company's progress and potential.
The healthcare company operates in two main areas: immunotherapy through Tevogen Bio, which develops off-the-shelf, genetically unmodified T cell therapeutics for infectious diseases and cancers, and artificial intelligence through Tevogen.AI, focused on enhancing drug discovery, clinical trial efficiency, and patient access. The company operates solely in the U.S. and maintains a tariff-insensitive position amid current market volatility.
CEO Dr. Ryan Saadi highlighted that insiders have only sold shares to satisfy tax obligations related to restricted stock vesting, further emphasizing their commitment to the company's mission of redefining the future of medicine.
Tevogen Bio (Nasdaq: TVGN) announced two key developments: First, CEO Ryan Saadi has been named to the 2025 Health Care Power List by NJBIZ, recognizing his leadership in healthcare innovation. Second, the company appointed David E. Banko as Global Head of Government Affairs and Patient Access, who will focus on advancing patient access and securing coding, coverage, and reimbursement pathways.
The company reaffirmed its previously announced topline forecast of $1 billion in launch year for Tevogen Bio Oncology and nearly $1 billion for Tevogen Bio Specialty Care. These developments align with the company's commercialization strategy as it continues to advance its AI-driven immunotherapy drug discovery platform.
Tevogen Bio (Nasdaq: TVGN) has appointed David E. Banko, CPA as Global Head of Government Affairs and Patient Access to advance its commercialization strategy. Banko brings over 30 years of experience in market access and health policy across pharma, medical devices, diagnostics, and hospital finance.
In his new role, Banko will lead market access strategies for Tevogen's product portfolio in oncology, virology, neurology, and rheumatology. His responsibilities include:
- Advancing patient access to therapies under development
- Engaging with government and private payers
- Ensuring Health Technology Assessment readiness
- Securing appropriate coding, coverage, and provider reimbursement at launch
- Leading policy engagement with the current administration
Banko's previous experience includes roles at Cordis Corp (former Johnson & Johnson company) and B. Braun Medical Inc., where he successfully shaped Medicare's national coverage policies and developed strategic global pricing initiatives.
Tevogen Bio (TVGN) has filed a new patent with the USPTO for an innovative T cell vaccine under development. Unlike traditional vaccines focusing on B cell response, this vaccine aims to stimulate T cell responses targeting the entire viral genome, similar to their lead product TVGN 489. The approach is designed to combat mutation risks by targeting multiple viral segments.
The vaccine development is powered by Tevogen.AI's PredicTcell technology for peptide identification. Initially focused on national security and U.S. military biological threat protection, the vaccine's application could be expanded based on needs. The development aligns with Tevogen's previously announced topline forecasts of $1 billion each for their Oncology and Specialty Care divisions.
Tevogen Bio (Nasdaq: TVGN) announced that its CIO & Head of Tevogen.AI, Mittul Mehta, participated as a featured speaker at Proskauer's AI discussion panel titled 'Attuned AI: Shaping AI to Empower Your Industry' on March 6, 2025, in New York City.
The panel, which included executives from Perplexity and Harvey, focused on AI's transformation of the finance, biotech, and legal sectors. Mehta discussed Tevogen.AI's approach to AI-driven biotech advancements, highlighting applications in precision medicine and operational efficiencies.
The event was moderated by Proskauer Partner Wai Choy, who praised Tevogen.AI's combination of proprietary datasets with generative AI models for biotech discovery and development.
Tevogen Bio (Nasdaq: TVGN) has secured the remaining $8 million grant from KRHP , completing a total $10 million non-dilutive funding package following positive progress review. The company reported efficient operations with operating expenses of $9.7 million for the first three quarters of 2024.
The additional funding was particularly influenced by advancements in Tevogen.AI, which has enhanced its PredicTcell platform through expanded viral and disease datasets, supported by wet lab science. Following a Microsoft partnership, Tevogen.AI is expanding its team to develop predictive models.
The grant, being non-dilutive, maintains shareholder value while contributing to the company's mission of developing therapies for cancers and viral infections.
Tevogen Bio (Nasdaq: TVGN) announced that Founder and CEO Ryan Saadi has been named to the 2025 NJBIZ Power 100, recognizing influential figures in New Jersey's business landscape. The clinical-stage specialty immunotherapy biotech company is developing affordable T cell therapies for viral infections and cancers.
The company's proprietary ExacTcell™ technology has demonstrated positive results in a proof-of-concept trial, with findings published in Blood Advances. A significant advancement in making therapies more accessible was marked by the launch of Tevogen.AI and a partnership with Microsoft.
Dr. Saadi, honored alongside Johnson & Johnson CEO Joaquin Duato, emphasized that this recognition reflects Tevogen's mission to challenge traditional biotech models by focusing on affordability, accessibility, and sustainability in drug development.
FAQ
What is the current stock price of Tevogen Bio (TVGN)?
What is the market cap of Tevogen Bio (TVGN)?
